A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)

• ClinicalTrials.gov Identifier: NCT02763319
• Recruitment Status: Active, not recruiting
• First Posted: May 5, 2016
• Last Update Posted: August 2, 2022
• Sponsor: MorphoSys AG
• Collaborator: ICON Clinical Research
• Information provided by (Responsible Party): MorphoSys AG

Tracking Information

• First Submitted Date: April 30, 2016
• First Posted Date: May 5, 2016
• Last Update Posted Date: August 2, 2022
• Study Start Date: June 2016
• Estimated Primary Completion Date: June 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 12, 2020)

Progression-free survival (PFS) [ Time Frame: From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 4 yrs ]

To determine the efficacy of a combination of MOR00208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in:

• Adult patients with R-R DLBCL (overall population)
• A subgroup of adult patients with R-R DLBCL with low baseline peripheral blood NK-cell count (NKCC-low)

Original Primary Outcome Measures (submitted: May 3, 2016)

Progression-free survival (PFS) [ Time Frame: From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 4 yrs ]

To determine the efficacy of a combination of MOR208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in adult patients with R-R DLBCL.

Current Secondary Outcome Measures (submitted: March 12, 2020)

• Objective response rate (ORR) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• Duration of response (DoR) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• overall survival (OS) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• disease control rate (DCR) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• time to progression (TTP) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• time to next treatment (TTNT) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• Number of patients with adverse events [ Time Frame: assessed up to 4 yrs ]
  Number of participants with treatment- and non-treatment related adverse events as assessed by CTCAE
• quality of life (QoL) [ Time Frame: assessed up to 4 yrs ]
  EORTC QLQ-C30 and EQ-5D-5L questionnaires will be used
• Number of patients developing Tafasitamab antibodies [ Time Frame: assessed up to 2 yrs ]
• Maximum Plasma Concentration of Tafasitamab (Cmax) [ Time Frame: assessed up to 2 yrs ]
• Apparent trough concentration (Cpd) of Tafsitamab [ Time Frame: assessed up to 2 yrs ]

Original Secondary Outcome Measures (submitted: May 3, 2016)

• Objective response rate (ORR) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• Duration of response (DoR) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• overall survival (OS) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• disease control rate (DCR) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• time to progression (TTP) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• time to next treatment (TTNT) [ Time Frame: From date of randomization assessed up to 4 yrs ]
  To determine efficacy
• Number of patients with adverse events [ Time Frame: assessed up to 4 yrs ]
  Number of participants with treatment- and non-treatment related adverse events as assessed by CTCAE
• quality of life (QoL) [ Time Frame: assessed up to 4 yrs ]
  EORTC QLQ-C30 questionnaire will be used
• Number of patients developing MOR208 antibodies [ Time Frame: assessed up to 2 yrs ]
• Maximum Plasma Concentration of MOR208 (Cmax) [ Time Frame: assessed up to 2 yrs ]
• Apparent trough concentration (Cpd) of MOR00208 [ Time Frame: assessed up to 2 yrs ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
• Official Title: A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
• Brief Summary: The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
• Detailed Description: This is a randomised, two-arm, multicentre, open-label phase II/III efficacy and safety study of Tafasitamab in combination with BEN versus RTX in combination with BEN given to adult patients who have relapsed after or are refractory to at least one but no more than three prior systemic therapies and have failed, or are not candidates for HDC and ASCT, and have thus exhausted their therapeutic options of demonstrated clinical benefit. At least one prior therapy line must have included a CD20-targeted therapy.
• Study Type: Interventional
• Study Phase: Phase 2; Phase 3

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:

Outcome assessor: blinding on treatment group

Primary Purpose: Treatment

• Condition: Diffuse Large B-cell Lymphoma

Intervention

• Drug: Rituximab (RTX)
  Rituximab: Dose: 375 mg/m2 IV
  Other Names:

  • Rituxan
  • Mab Thera
• Drug: Tafasitamab
  Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
• Drug: Bendamustine (BEN)
  Other Name: Levact/Treanda

Study Arms

• Experimental: Tafasitamab and bendamustine
  Tafasitamab and bendamustine
  Interventions:

  • Drug: Tafasitamab
  • Drug: Bendamustine (BEN)
• Active Comparator: Rituximab and bendamustine
  Rituximab and bendamustine
  Interventions:

  • Drug: Rituximab (RTX)
  • Drug: Bendamustine (BEN)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: March 12, 2020): 450
• Original Estimated Enrollment (submitted: May 3, 2016): 330
• Estimated Study Completion Date: June 2024
• Estimated Primary Completion Date: June 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

INCLUSION CRITERIA:

1. Age ≥18 years
2. Histologically confirmed diagnosis, according to the World Health Organization (WHO, 2008) classification, of: DLBCL NOS, THRLBCL, EBV-positive DLBCL, composite lymphoma with a DLBCL component with a DLBCL relapse subsequent to DLBCL treatment, disease transformed from an earlier diagnosis of low grade lymphoma (i.e. an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with a DLBCL relapse subsequent to DLBCL treatment.
3. Fresh tumour tissue for central pathology review must be provided as an adjunct to participation in this study. Should it not be possible to obtain a fresh tumour tissue sample, archival paraffin embedded tumour tissue acquired ≤3 years prior to screening for this protocol must be available for this purpose.

4. Patients must have:

   1. relapsed or refractory DLBCL
   2. at least one bidimensionally measurable disease site. The lesion must have a greatest transverse diameter of ≥1.5 cm and greatest perpendicular diameter of ≥1.0 cm at baseline. The lesion must be positive on PET scan
   3. received at least one, but no more than three previous systemic therapy lines for the treatment of DLBCL. At least one previous therapy line must have included a CD20-targeted.
   4. ECOG 0 to 2
5. Patients after failure of ASCT or patients considered in the opinion of the investigator currently not eligible for HDC with subsequent ASCT.

6. Patients must meet the following laboratory criteria at Screening:

   1. ANC ≥1.5 × 109/L (unless secondary to bone marrow involvement by DLBCL)
   2. PLTs ≥90 × 109/L (unless secondary to bone marrow involvement by DLBCL) and absence of active bleeding
   3. total serum bilirubin ≤2.5 × ULN unless secondary to Gilbert's syndrome (or pattern consistent with Gilbert's) or documented liver involvement by lymphoma. Patients with Gilbert's syndrome or documented liver involvement by lymphoma may be included if their total bilirubin is ≤5 x ULN
   4. ALT, AST and AP ≤3 × ULN or <5 × ULN in cases of documented liver involvement by lymphoma
   5. serum creatinine ≤2.0 x ULN or creatinine clearance must be ≥40 mL/min calculated using a standard Cockcroft-Gault formula (Cockroft & Gault, 1976)
7. For a female of childbearing potential (FCBP), a negative pregnancy test must be confirmed before enrolment. An FCBP must commit to take highly effective contraceptive precautions without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. An FCBP must refrain from breastfeeding and donating blood or oocytes during the course of the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. Restrictions concerning blood donations apply as well to females who are not of childbearing potential.
8. Males must use an effective barrier method of contraception without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later, if the patient is sexually active with an FCBP. Males must refrain from donating blood or sperm during study participation and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later.

9. In the opinion of the investigator, the patients must:

   1. be able to comply with all study-related procedures, medication use, and evaluations
   2. be able to understand and give informed consent
   3. not be considered to be potentially unreliable and/or not cooperative.

EXCLUSION CRITERIA:

1. Patients who have: any other histological type of lymphoma including, e.g., primary mediastinal (thymic) large B-cell lymphoma (PMBL) or Burkitt's lymphoma, primary refractory DLBCL, patients with known "double/triple hit" DLBCL genetics, CNS lymphoma involvement in present or past medical history
2. Patients who had a major surgery less than 30 days prior to Day 1 dosing

3. Patients who have, within 14 days prior to Day 1 dosing:

   1. not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma-specific therapy
   2. received live vaccines
   3. required parenteral antimicrobial therapy for active, intercurrent systemic infections

4. Patients who:

   1. in the opinion of the investigator, have not recovered sufficiently from the adverse toxic effects of prior therapies, major surgeries or significant traumatic injuries
   2. were previously treated with CD19-targeted therapy or BEN
   3. have a history of previous severe allergic reactions to compounds of similar biological or chemical composition to Tafasitamab, RTX, murine proteins or BEN, or the excipients contained in the study drug formulations
   4. have undergone ASCT within a period of ≤3 months prior to signing the informed consent form. Patients who have a more distant history of ASCT must exhibit full haematological recovery before enrolment into the study.
   5. have undergone previous allogeneic stem cell transplantation
   6. concurrently use other anticancer or experimental treatments

5. Prior history of malignancies other than DLBCL, unless the patient has been free of the disease for ≥3 years prior to Screening. Exceptions to the ≥3-year time limit include history of the following:

   1. basal cell carcinoma of the skin
   2. squamous cell carcinoma of the skin
   3. carcinoma in situ of the cervix, breast and bladder

   f) incidental histological finding of prostate cancer (Tumour/Node/Metastasis [TNM] stage of T1a or T1b)

6. Patients with:

   1. positive hepatitis B and/or C serology
   2. known seropositivity for or history of active viral infection with HIV
   3. evidence of active, severe uncontrolled systemic infections or sepsis
   4. a history or evidence of severely immunocompromised state
   5. a history or evidence of severe hepatic impairment (total serum bilirubin > 3 mg/dL), jaundice unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma
   6. a history or evidence of clinically significant cardiovascular, cerebrovascular, CNS and/or other disease that, in the investigator's opinion, would preclude participation in the study or compromise the patient's ability to give informed consent

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Austria, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Poland, Portugal, Romania, Serbia, Singapore, Spain, Taiwan, Turkey, United Kingdom, United States
• Removed Location Countries: Czech Republic

Administrative Information

• NCT Number: NCT02763319
• Other Study ID Numbers: MOR208C204; 2014-004689-11 ( EudraCT Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: MorphoSys AG
• Original Responsible Party: Same as current
• Current Study Sponsor: MorphoSys AG
• Original Study Sponsor: Same as current
• Collaborators: ICON Clinical Research
• Investigators: Not Provided
• PRS Account: MorphoSys AG
• Verification Date: August 2022